Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Current Assets: 2020-2025

Historic Current Assets for Mereo BioPharma Group (MREO) over the last 2 years, with Sep 2025 value amounting to $52.4 million.

  • Mereo BioPharma Group's Current Assets fell 39.57% to $52.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.4 million, marking a year-over-year decrease of 39.57%. This contributed to the annual value of $74.8 million for FY2024, which is 17.26% up from last year.
  • As of Q3 2025, Mereo BioPharma Group's Current Assets stood at $52.4 million, which was down 14.68% from $61.4 million recorded in Q2 2025.
  • In the past 5 years, Mereo BioPharma Group's Current Assets ranged from a high of $168.2 million in Q2 2021 and a low of $52.4 million during Q3 2025.
  • Its 3-year average for Current Assets is $69.2 million, with a median of $65.3 million in 2023.
  • Per our database at Business Quant, Mereo BioPharma Group's Current Assets soared by 241.10% in 2021 and then slumped by 43.84% in 2022.
  • Mereo BioPharma Group's Current Assets (Quarterly) stood at $133.9 million in 2021, then tumbled by 43.84% to $75.2 million in 2022, then declined by 15.21% to $63.8 million in 2023, then grew by 17.26% to $74.8 million in 2024, then plummeted by 39.57% to $52.4 million in 2025.
  • Its Current Assets stands at $52.4 million for Q3 2025, versus $61.4 million for Q2 2025 and $66.9 million for Q1 2025.